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INTRODUCTION
With the advent of modern chemotherapeutic regimens
and supra-voltage radiation therapy, Hodgkin’s disease (HD)
is largely curative with frontline therapy [1]. Nonetheless,
approximately 25% of patients fail to achieve a complete
response (CR). An additional 30% to 35% of patients will
achieve a CR but subsequently succumb to relapse.
Standard salvage therapy has not yielded durable remis-
sions [2,3]. Although radiotherapy has been shown to be
safe as a salvage regimen, few patients are able to benefit
[4-6]. Over the past 2 decades, autologous hematopoietic
cell transplantation (HCT) has emerged as a potentially
curative treatment for patients with either relapsed or
refractory HD [7]. This therapeutic modality utilizes the
principle of overcoming drug resistance with dose escala-
tion supported by hematopoietic cell rescue, a concept that
has been tested in other malignancies. Most trials have
demonstrated a beneﬁt in terms of freedom from progres-
sion (FFP) for patients with relapsed or refractory HD [8-
17]. Nonetheless, relapse remains one of the leading causes
of failure after autologous HCT.
A variety of preparatory regimens have been used with
autologous HCT. Regimens containing total body irradia-
tion (TBI) have not demonstrated clear superiority over
chemotherapy-only regimens, although they have not been
directly compared in clinical trials [18,19]. In addition, an
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ABSTRACT
High-dose CBV (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves sur-
vival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin’s disease (HD). However, carmustine
(BCNU) dose-dependent pulmonary toxicity occurs in 20% to 30% of patients. A decreased incidence of interstitial
pneumonitis as well as a possible benefit in efficacy has been reported with lomustine (CCNU) compared to BCNU
in the standard dose setting. In a dose-escalation study, we substituted CCNU for BCNU in the CBV regimen for
16 patients with HD (n = 12) or non-Hodgkin’s lymphoma (n = 4). Based on the promising results, an additional 47
consecutive patients with HD were treated with the following regimen: CCNU (15 mg/kg) orally on day –6, etopo-
side (60 mg/kg) intravenously on day –4, and cyclophosphamide (100 mg/kg) intravenously on day –2. Peripheral
blood progenitor cells and/or bone marrow were infused on day 0. With a median follow-up for the surviving
patients of 3.2 years (range, 0.8-9.9 years), the 3-year overall survival rate was 57% (CI, ±15%), event-free survival
was 52% (CI, ±14%), and freedom from progression was 68% (CI, ±14%). There were 21 deaths, 10 due to HD. Six
patients died due to respiratory failure. Interstitial pneumonitis occurred in 63% of patients and could not be corre-
lated with prior chest radiotherapy. This regimen demonstrated survival rates similar to those of historical studies
that used the CBV regimen. However, the incidence of interstitial pneumonitis was in excess of expected.
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increased risk of pulmonary complications was seen among
patients who had received prior chest radiotherapy [20].
The CBV regimen (cyclophosphamide, carmustine, and
etoposide) developed at MD Anderson and its various modi-
fications have been widely employed prior to autologous
transplantation. In multiple studies, patients with relapsed
HD were shown to have actuarial survival rates of approxi-
mately 50%, with failure-free survival rates of 40%
[19,21-24]. Other regimens, such as BEAM (carmustine,
etoposide, cytarabine, and melphalan), have also shown
promising results [25-29]. However, most of these carmustine
(BCNU)-containing regimens are limited by dose-related
toxicities, particularly a 20% to 30% risk of developing
interstitial pneumonitis [30-35]. Potentially related to inhi-
bition of glutathione reductase in alveolar macrophages,
BCNU-related interstitial pneumonitis was recognized as
early as 1979 [36]. Multiple studies have since demonstrated
a clear dose-response relationship, particularly with large
cumulative doses [37-39]. Furthermore, chest radiotherapy
delivered within 2 to 3 months of autologous HCT further
increases the risk of pulmonary toxicity [32,40].
The concern of increased risk of pulmonary toxicity
from currently available therapy and the exclusion of many
patients with impaired pulmonary function from prior ther-
apy led to the development of a new preparatory regimen at
our institution. Our study was based on a trial by the Cancer
and Leukemia Group B (CALGB) in which patients with
advanced, previously treated HD were treated with BCNU
(200 mg/m2) or lomustine (CCNU) (100 mg/m2), resulting
in objective responses of 36% and 69%, respectively [41].
CCNU is reported to have less pulmonary toxicity than
BCNU at standard doses [42,43] and, therefore, was substi-
tuted for BCNU or TBI. In a dose-escalation phase I study,
a total of 21 patients with either single-breath carbon
monoxide diffusion capacity (DLCO) ≤60%, recent chest
irradiation, or interstitial pneumonitis (HD, n = 12; non-
Hodgkin’s lymphoma, n = 9) were enrolled. An initial dose
of 6 mg/kg was used and was increased by 3 mg/kg in
each subsequent group of 4 patients. The trial was stopped
at 15 mg/kg because of the development of interstitial pneu-
monitis in 2 of 9 patients. Compared with a concurrent
group treated with CBV, there were no differences in dis-
ease-free survival rates [44].
We now present the results of a phase II trial conducted
to determine both the efﬁcacy and incidence of interstitial
pneumonitis of CCNU at the previously ascertained maxi-
mal tolerated dose.
MATERIALS AND METHODS
Patient Selection
From September 1989 through December 1997, 59 patients
(including those in the phase I study) with refractory or
recurrent HD referred to the Division of Bone Marrow
Transplantation at Stanford University Medical Center were
enrolled in this study. The ﬁrst 12 patients were previously
described in the published phase I trial [44]. Selection crite-
ria included age ≤70 years, Karnofsky score ≥70, normal
bone marrow cytogenetics, no medical contraindications to
the proposed therapy, and evidence of relapsed or refractory
HD. Pathological confirmation of disease or unequivocal
radiographic studies were required to establish the current
state of disease. The respective specialists at Stanford Uni-
versity Medical Center reviewed all pertinent studies.
Potential patients were presented at the weekly new patient
conference to determine trial eligibility. Additional eligibil-
ity for the 12 patients enrolled in the pilot study included
DLCO ≤60%, history of recent or active pneumonitis, or
recent chest radiotherapy. The remaining 47 patients were
not limited by these criteria. All patients gave written
informed consent prior to being enrolled in this study.
Cytoreduction
Prior to high-dose chemotherapy, most patients received
1 to 3 cycles of conventional combination chemotherapy in
an attempt to achieve a minimal disease state, defined as
≥75% reduction in a bulky mass (≥10 cm), no individual
lymph node >2 cm in maximum diameter, and <10% bone
marrow involvement. Patients with a residual mass but a
negative positron emission tomography (PET) scan, gallium
scan, or biopsy were considered to be in a complete remis-
sion. The choice of cytoreductive therapy was based on the
remission duration and prior therapy. In general, patients
who had initially received a 4-drug regimen or whose disease
persisted or progressed after 1 to 2 cycles of standard therapy
were treated with a 3- or 4-drug non-cross-resistant combi-
nation regimen. For those patients that had previously
received a 7- or 8-drug regimen, DHAP cytoreductive ther-
apy (decadron, cytarabine, and cisplatin) was used. A subset
of patients whose disease had recurred 12 months or more
after the initial chemotherapy was treated with therapy simi-
lar to the original induction chemotherapy. Twenty patients
received high-dose cyclophosphamide and/or etoposide for
peripheral blood progenitor cell (PBPC) mobilization, pro-
viding further cytoreductive therapy. A total of 27 patients
required 2 or more cycles of chemotherapy due to persistent
or progressive disease after the initial cytoreductive regimen.
One patient did not receive cytoreductive therapy but rather
proceeded directly to high-dose chemotherapy with persis-
tent disease after initial therapy.
High-Dose Therapy
The initial 12 patients were part of the phase I dose-
escalation trial, receiving CCNU at doses (based on ideal
body weight) of 6 mg/kg (n = 2), 9 mg/kg (n = 3), 12 mg/kg
(n = 4), or 15 mg/kg (n = 3) orally on day –6. All subsequent
47 patients in the phase II trial received 15 mg/kg. All
patients then received the following drugs of the prepara-
tory regimen: etoposide 60 mg/kg (based on actual body
weight) intravenously over 4 hours on day –4 and cyclo-
phosphamide 100 mg/kg (based on ideal body weight) intra-
venously over 2 hours on day –2. On day 0, all patients
received autologous hematopoietic cell infusion via a large-
bore central venous catheter over 5 to 10 minutes.
Source of Hematopoietic Progenitor Cells
The initial patient enrolled in the study engrafted slowly
after autologous bone marrow (BM) infusion as previously
described, with 10% bone marrow cellularity at 60 days. All
subsequent patients received hematopoietic cell transplanta-
tion with either PBPC alone (n = 52) or a combination of
PBPC and BM (n = 6) if peripheral blood stem cell (PBSC)
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collection was <5 × 107 total nucleated cells/kg patient weight.
The procedure for PBPC collection has been previously
described [45-50]. PBPCs were mobilized with granulocyte
colony-stimulating factor (G-CSF). In addition, patients
received the following chemotherapeutic regimens for the
purpose of cytoreduction and mobilization: DHAP (n = 21),
cyclophosphamide (4 g/m2) (n = 6), VP16 (2 g/m2) (n = 13),
and sequential cycles of cyclophosphamide and VP16 (n = 1).
Supportive Care
All patients received supportive care as previously
described [19]. All patients received nonabsorbable antibi-
otics or ciprofloxacin to prevent gastrointestinal contam-
ination. Broad-spectrum antibiotics were given for fever
during the time of neutropenia and tailored appropriately
based on culture results. Blood products were irradiated
and cytomegalovirus (CMV) negative products were used
for CMV-negative patients. Platelet counts were main-
tained at 10,000/µL and hemoglobin kept at 10 g/dL with
the use of transfusions.
Follow-Up
Patients were closely evaluated at the medical center for
the ﬁrst 60 days posttransplantation, or longer as clinically
indicated. Patients were subsequently followed by their
referring physician with the following recommendations:
physical examination, chest x-ray, and blood studies every
1 to 2 months for the first year following transplantation;
every 3 months for the second year; every 4 months for the
third year; every 6 months for the fourth year; and annually
thereafter. BM biopsies were performed at days 30, 60, and
100 to assess engraftment status and annually to determine
disease involvement or cytogenetic abnormalities. Com-
puted tomography (CT) scans were recommended at least
every 6 months during the ﬁrst 2 years posttransplantation,
and more often as indicated. Subsequently, CT scans were
recommended on an annual basis through 5 years after
transplantation.
Posttransplantation Irradiation
A total of 14 patients received external beam radiation
therapy (XRT) to 1 or more sites after transplantation as a
part of planned post-HCT therapy. Sites of irradiation
included: mantle (n = 5), mediastinal (n = 3), hilar (n = 1), axil-
lary (n = 3), supraclavicular fossae (n = 2), para-aortic (n = 2),
mesenteric (n = 1), inguinal (n = 2), and pelvis (n = 1). Two
patients received XRT at sites of relapse after transplant.
Diagnosis of Interstitial Pneumonitis
Baseline pulmonary function tests (PFTs), including
forced vital capacity (FVC), forced expiratory volume (FEV1)
and DLCO, were obtained prior to study registration. Addi-
tional PFTs were performed if signs/symptoms of pulmonary
toxicity developed. DLCO was corrected for hemoglobin
(Hb) using the formula: (1.7 × Hb)/(10.2 + Hb). FVC, FEV1,
and DLCO were expressed as percentages predicted for the
corresponding age, sex, and height of the patient. At least
2 of the following criteria were required for the diagnosis of
interstitial pneumonitis: (1) symptoms of cough, shortness of
breath, nausea/vomiting, prolonged fatigue, and/or failure to
thrive, (2) a relative drop in adjusted DLCO of ≥20%, (3)
chest radiograph abnormalities, and (4) bronchoalveolar
lavage demonstrating only inflammatory changes. Routine
testing was performed to exclude Pneumocystis carinii pneu-
monia, bacterial, viral, and fungal etiologies. All patients
diagnosed with interstitial pneumonitis received prednisone
therapy beginning at 1 mg/kg per day and tapered by 10 mg
weekly as tolerated. Patients treated with prednisone
received concurrent Pneumocystis prophylaxis with oral sul-
famethoxasole-trimethoprim or aerosolized pentamidine.
Routine antifungal therapy was not administered.
Statistical Methods
The Kaplan-Meier method was used to estimate the
probabilities of overall survival (OS), event-free survival
(EFS), and FFP over time [51]. Disease progression and
death from any cause defined events in the calculation of
EFS. In estimating FFP, recurrence of HD was the only
event deﬁned. All calculations were made from the time of
transplantation. Log-rank statistics were used to compare
chemotherapy regimens. Patient characteristics, disease
states, and extranodal involvement were individually tested
with univariate analysis for each of the outcome variables
(OS, EFS, FFP) and compared using the log-rank test. The
chi-square method was used to compare both pre- and post-
transplantation XRT and the development of posttransplan-
tation interstitial pneumonitis.
RESULTS
Patient Population
The characteristics of the 59 patients are outlined in
Tables 1 and 2. This group consisted of 27 female and 32 male
patients. The median age at diagnosis of HD was 24 years
(range, 10-64 years), and the median age at the time of autolo-
gous HCT was 27 years (range, 11-66 years). The majority of
patients had at least stage II disease, with 45% of patients hav-
ing constitutional symptoms at the time of diagnosis.
Sixteen patients were considered to have failed induc-
tion therapy, deﬁned as progression during induction therapy
Table 1. Patient Characteristics
Characteristics n (%)
Median age at HCT, years (range) 27 (11-66)
Sex
Female 27 (45.8)
Male 32 (54.2)
Histology
Nodular sclerosing 52 (88.1)
Mixed cellular 7 (11.9)
Stage at diagnosis
I 1 (1.7)
II 24 (40.7)
III 18 (30.5)
IV 16 (27.1)
Constitutional symptoms at diagnosis
No 36 (61.1)
Yes 23 (38.9)
Disease state at HCT
Relapse 40 (67.8)
Resistant 14 (23.7)
Resistant relapse 5 (8.5)
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(n = 7), progression within 60 days of completing therapy
(n = 7), or incomplete response (n = 2) based on biopsy, gal-
lium scan, or PET scan. Forty-three patients had attained a
CR after induction therapy and subsequently suffered a
relapse of their disease. This group included patients with a
residual mass at the completion of induction therapy based
on radiographic or CT scan ﬁndings only. Of the 46 patients
with relapse of their disease, 36 received transplants after
their first relapse. Twenty-three patients relapsed at the
sites of original disease, whereas 13 relapsed at new sites.
An additional 7 patients received transplants after their
second relapse. The disease status of patients at transplanta-
tion, largely reﬂecting the efﬁcacy of conventional cytore-
ductive therapy, was as follows: 20 patients achieved a CR;
23 patients achieved a partial response; and 16 patients had
persistent or progressive disease.
Twenty-five patients received radiotherapy (XRT) as
part of initial therapy, as either single or multi-modality
therapy. Twenty-four patients received thoracic irradiation
(mantle/modiﬁed mantle [n = 16], subtotal lymphoid [n = 7],
or cervical/subclavian [n = 1]). Six patients relapsed in the
irradiated field, whereas 15 patients relapsed outside the
XRT port. The remaining 4 patients had evidence of persis-
tent or progressive disease. An additional 21 patients,
including 3 patients who had previously received XRT, were
treated with XRT as a means of salvage therapy. Involved
ﬁeld radiotherapy was delivered to the thorax in 17 patients
(mantle/modiﬁed mantle [n = 11], subtotal lymphoid [n = 4],
bronchus [n = 1], or splenic/minimantle [n = 1]). Three
patients received salvage radiotherapy at other sites
(inguinal [n = 2], liver [n = 1]). At the time of transplant,
13 of these patients had persistent disease.
Survival Data
Figure 1 demonstrates the actuarial survival curves based
on the method of Kaplan-Meier for all 59 patients. The
median follow-up of surviving patients was 3.2 years (range,
0.8-9.9 years). The 3-year OS was 57% (conﬁdence interval
[CI], ±15%); FFP was 68% (CI, ±14%); and EFS was 52%
(CI, ±14%). Sixteen patients have developed recurrent HD,
with a median time to relapse of 1.9 years (range, 69 days to
4.2 years). Of the 13 evaluable patients (records were not
available for 3 patients), 10 patients relapsed at sites of previ-
ous disease, whereas 3 patients relapsed in new sites. FFP
was 75% for patients who achieved a CR after induction
therapy and 51% for those who were considered to have
failed induction therapy (P = .21). Twenty-one deaths have
occurred among the 59 patients, of which 10 were due to
progressive HD and 11 were due to other causes (Table 3).
Interstitial Pneumonitis
Six patients had interstitial pneumonitis prior to high-
dose chemotherapy. Three patients had an exacerbation after
transplantation, whereas 34 patients (62.7%) had newly diag-
nosed interstitial pneumonitis after HCT. The median drop
in DLCO was 24% (range, 13%-61%). Of 41 patients who
received thoracic XRT prior to transplantation, 25 developed
post-HCT interstitial pneumonitis (P = .90). All patients who
received XRT within 6 months of transplantation developed
interstitial pneumonitis. Ten patients received thoracic XRT
posttransplantation. Of these patients, 4 developed intersti-
tial pneumonitis prior to initiation of XRT and 3 developed
interstitial pneumonitis following XRT. All patients with
interstitial pneumonitis were treated with prednisone taper-
ing therapy beginning at 1 mg/kg per day.
Other Toxicities
The Southwest Oncology Group (SWOG) toxicity scale
was used to determine acute toxicity, defined as occurring
within the ﬁrst 100 days after transplantation (Table 4). All
patients developed grade 4 hematologic (pancytopenia) and
grade 2-3 gastrointestinal toxicity with nausea/vomiting. Sev-
enty-two percent of patients had fevers during the time of
neutropenia, requiring the use of antibiotics. A source of
infection was determined in only 20% of these patients.
There were 3 gram-negative infections and 7 gram-positive
infections. Two patients had blood culture–positive Candida
infections. An additional patient had evidence of fungal infec-
tion by CT scans and improved with antifungal treatment.
More than 50% of the patients had oropharyngeal mucositis,
with the majority categorized as grade 3-4 severity.
DISCUSSION
Large cumulative doses and prolonged administration of
BCNU are associated with increased pulmonary toxicity.
Table 2. Treatment History*
n 
Initial induction therapy
CT 34
RT 7
CT + RT 18
Initial remission duration†
Induction failure 16
61-365 days 17
>365 days 24
No. of drugs in initial course of treatment
None 7
≤4 26
>4 26
No. cytoreductive regimens
None 2
1 29
2 20
>2 8
RT 20
Chemotherapy regimens
ABVD 47
MOPP 35
DHAP 34
High-dose etoposide 18
Stanford V 11
High-dose cyclophosphamide 7
COPP + adriamycin 3
CHOP 3
Other 8
Relapse in previously irradiated sites 25
Inside RT site 10
Outside RT site 15
*CT indicates chemotherapy; RT, radiotherapy.
†Does not include patients who were treated only with RT.
M.J. Stuart et al.
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Lung damage has been observed in >50% patients receiving
total doses >1500 mg/m2 BCNU [52]. CBV, which is the
most commonly used high-dose preparatory regimen for
HD, has notable increases of interstitial pneumonitis
depending on the dose of BCNU. In a dose-ﬁnding study
for CBV, Wheeler et al. demonstrated that patients who
received BCNU at doses of 600 mg/m2 had a 28% incidence
of interstitial pneumonitis compared to a 4% incidence in
those patients who received doses of 450 mg/m2 [31,53-56].
Similar results were seen in a series of 51 consecutive
patients with relapsed HD who were treated with CBV and
autologous HCT with a BCNU dose of >600 mg/m2 [35].
The addition of high-dose cyclophosphamide may further
exacerbate lung injury [36,57].
Prior exposure to mediastinal XRT may cause intersti-
tial pneumonitis and may have an additive effect with HCT,
particularly if delivered in close temporal proximity [58].
Weaver at al. evaluated the use of CBV in patients with lym-
phoid malignancies who had received prior radiation ther-
apy. Twenty-three percent of patients who received a
BCNU dose of 600 mg/m2 developed interstitial pneumoni-
tis. Furthermore, 83% of patients who received mantle XRT
within 3 months of transplantation developed interstitial
pneumonitis [32].
Similar to BCNU, CCNU is a chloroethyl nitrosourea
with known efficacy as a single agent in the treatment of
HD. In a study conducted by the CALGB, standard CCNU
compared favorably to BCNU salvage therapy for patients
with advanced disease [41]. Additionally, CCNU has been
used in combination therapy for advanced HD, with 39% to
75% CR rates depending on prior therapy and the regimen
used [59]. Although available only in oral formulation and,
therefore, subject to bioavailability, high-performance liquid
chromatography data suggest ability to achieve high blood
levels of the 2 active metabolites (trans- and cis-4-hydoxy
lomustine) [60].
Prior studies have suggested a decrease in incidence of
pulmonary toxicity with CCNU at doses below 950 mg/m2
[61]. Our phase I study included patients who otherwise
would have been excluded from HCT due to a compromise
in pulmonary function. No universal toxicity relative to this
drug was noted, and engraftment was prompt. Although
5 patients experienced interstitial pneumonitis, it was con-
sidered to be the consequence of active or recent interstitial
pneumonitis and/or mantle irradiation. In this earlier study,
a single patient had pneumonitis that could be clearly attrib-
uted to CCNU alone [44].
Horning et al. previously compared 3 preparatory regi-
mens in patients with HD. The standard regimen of CBV
was used in patients with previous exposure to mantle or
pelvic irradiation. Fractionated TBI (given in 10 120-cGy
fractions) was substituted for BCNU in those patients
without previous or planned radiotherapy. Nineteen
patients (12 who were part of our phase I study) with pul-
monary impairment due to chemical or radiation pneu-
monitis instead received the CCNU-based regimen
(15 mg/kg). No significant differences in survival or
relapse were noted with the 3 regimens. However, patients
in the CCNU group had less favorable disease status than
did those in the other groups [19].
Survival data for 59 patients with recurrent or refractory Hodgkin’s disease treated with lomustine/etoposide/cyclophosphamide and autologous
hematopoietic cell transplantation.
Table 3. Causes of Death
Cause of Death No. of Patients (n = 21)
Relapse 10
Respiratory failure 6
Veno-occlusive disease 1
Sepsis 1
Secondary cancer 2
Cardiac failure 1
CCNU-Containing Chemotherapy and Autologous HCT in Hodgkin’s Disease
557B B & M T
With these encouraging results, we sought to further
study this CCNU-based regimen in patients with HD using
the previously tested maximum tolerated dose (15 mg/kg).
This trial was not limited to patients with poor pulmonary
function or recent radiotherapy except for those included
from the phase I trial. Instead, 47 consecutive patients with
relapsed or refractory disease were treated with this new
preparatory regimen followed by autologous HCT.
The high incidence of interstitial pneumonitis in our
study exceeds comparative studies with BCNU. Our deﬁni-
tion of interstitial pneumonitis may be more accurately
termed CCNU-related inﬂammatory syndrome to account
for those patients with predominantly gastrointestinal symp-
toms at presentation. Although pharmacokinetic studies
demonstrated preferential pulmonary toxicity that may
account for the higher incidence of pulmonary symptoms
[62,63], an association with noncholestatic liver enzyme
abnormalities has been previously documented [64]. In addi-
tion, administration of BCNU or CCNU in mice has been
shown to have effects on glutathione reductase in multiple
organs, including liver, heart, and kidneys [65].
Pneumonitis occurred in 37 patients (63%) after trans-
plantation. However, the increased incidence of interstitial
pneumonitis may be only partially accounted for by our
broader definition. In our series, only 4 patients had gas-
trointestinal symptoms or failure to thrive symptoms in the
absence of pulmonary symptoms. In addition, it must be
noted that the initial 12 patients would have otherwise been
excluded from autologous HCT due to preexisting intersti-
tial pneumonitis or DLCO <60%. Furthermore, review of
the literature suggests that our requirement of ≥20% decline
in DLCO may be more stringent [34,64].
Twenty-ﬁve of the patients (61%) who developed inter-
stitial pneumonitis after transplantation had received chest
radiotherapy prior to HCT. Prior exposure to radiotherapy
does not fully account for the high incidence of interstitial
pneumonitis (P = .90). The interval between chest radio-
therapy and HCT was >6 months in 75% of the patients.
However, all patients who received HCT within 6 months
of chest radiotherapy developed interstitial pneumonitis.
Thus, radiotherapy may have played an additive role in
those few patients.
The use of chemotherapeutic agents with known poten-
tial pulmonary toxicity may contribute to the development
of pneumonitis. In particular, bleomycin and procarbazine
have been associated with pulmonary toxicity. Because all
patients enrolled in this trial had received at least 1 such
agent, multivariate analysis was not performed to include
prior chemotherapeutic agents.
All patients diagnosed with interstitial pneumonitis
received treatment with prednisone therapy for a minimum
of 6 weeks. A signiﬁcant decline in performance status was
noted in all patients. Ten patients required oxygen therapy
at the time of diagnosis, and 4 of these patients required
mechanical ventilatory support. Furthermore, late recur-
rences were noted in 3 patients who did not receive consol-
idative radiotherapy. Routine fungal prophylaxis was not
performed, and an increased incidence of fungal infections
was not noted. However, more than 50% of the patients
with pneumonitis developed herpes zoster (data not shown).
Hematologic and gastrointestinal toxicities constitute
the other major toxicities seen with this regimen. Grade 3-4
mucositis occurred in 57% of the patients. All patients
developed pancytopenia following this regimen, as would be
expected. The majority of patients developed fevers at the
time of neutropenia which resolved with engraftment. Of
the documented infections, the most common were gram-
positive bacterial infections. No patient developed a fatal
fungal infection.
Our data demonstrate an EFS of 52%, an OS of 57%,
and FFP of 68% at 3 years. These results are comparable
with historical studies using the CBV regimen. Carella et al.
demonstrated CR rates of 53% in 128 patients with relapsed
and refractory disease [13]. In a study of 56 patients who
relapsed after MOPP (mechlorethamine, vincristine, procar-
bazine, prednisone) or ABVD (adriamycin, bleomycin, vin-
blastine, daccarbazine) therapy and received an autologous
transplant with the CBV regimen, Reece et al. estimated a
5-year OS of 53% and an EFS of 47% [56]. Other groups
have shown progression-free rates of 39% to 42% at 3 years
in groups with both relapsed and refractory disease [66,67].
A total of 21 patients have died, all within 3 years of
transplantation. Only half of the patients died due to a relapse
of HD. Treatment-related mortality (TRM), generally
deﬁned as death due to any cause other than disease within
first 100 days posttransplantation, occurred in 5 patients.
Causes of death included sepsis, respiratory failure, and car-
diac failure. Two patients died of respiratory failure due to
uncommon infectious diseases (CMV, Legionella) in this
setting. Another patient had evidence of bronchial obstruc-
tion of undetermined etiology. The overall 8% TRM is sim-
ilar to that seen by other centers and may be reﬂective of
improving supportive measures [18,34,66,68].
Many reports now include nonrelapse mortality, deﬁned
as death calculated from the time of transplantation. In our
series, 3 patients died of persistent or recurrent interstitial
pneumonitis almost 1 year after transplantation, demonstrating
Table 4. Toxicity Based on SWOG Toxicity Scale*
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac 1 0 1 2
Circulatory 0 3 4 1
Clotting 0 1 0 0
Dermatological 4 15 0 0
Endocrine 0 2 0 0
Eye 2 0 0 0
Gastrointestinal 5 15 1 0 
(not including nausea)
Hematologic 0 0 0 59
Hemorrhage 0 1 0 1
Infection 0 2 38 2
Liver 1 1 2 2
Lung (not including IP) 1 2 2 4
Metabolic 0 0 1 0
Mucosal 0 6 15 13
Neurologic (other) 0 3 0 1
Neuromotor 0 0 1 0
Neurosensory 0 3 0 0
Renal/Bladder 1 3 2 1
Miscellaneous 1 2 1 0
*Data are number of patients. IP indicates interstitial pneumonitis.
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a potential delayed chemotherapeutic toxicity. Secondary
malignancies are a late transplantation complication, occurring
with a median time of 28 months from the diagnosis of HD
[69]. In our series, 1 patient developed adenocarcinoma within
24 months of transplantation, and another patient developed
secondary acute myeloid leukemia (AML) 9 months after
HCT. However, given the recent reports by the European
Group for Bone Marrow Transplantation (EBMT) and a col-
laborative British cohort, the risk of secondary malignancies
still remains. Although the risk of AML and myelodysplastic
syndrome has been shown to plateau by 5 to 10 years, the risk
for solid tumors continues beyond 15 years [70,71].
Multiple prognostic factors for patients with HD under-
going autologous HCT have been analyzed. The most con-
sistent prognostic factor has been the difference in outcome
between those patients who demonstrate chemosensitivity
prior to transplantation and those with primary refractory
disease. In our analysis, demonstration of either responsive-
ness to chemotherapy prior to transplantation or achievement
of a CR after induction therapy results in a trend toward
improvement in the relapse rate but not in OS. Similarly, the
presence of extranodal disease in the 43 patients who relapsed
correlates with a trend toward an increased incidence of
relapse after transplantation (P = .08). The relatively small
sample size in our patient population limits a meaningful
analysis of other previously published prognostic factors.
Overall, our study shows comparable survival data when
CCNU is substituted for BCNU in the standard CBV
preparatory regimen. Chemoresistant disease and extranodal
involvement are likely poor risk factors in this patient popu-
lation. However, the incidence of interstitial pneumonitis
with high-dose CCNU exceeded prior studies with BCNU.
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